By asianet
With a theme centered on developing Guan Xian (Guan County) into a fertile land of glossy ganoderma (a type of mushroom), which is known for health benefits, the China Guan Xian Glossy Ganoderma Whole Industry Chain Development Conference was held from August 19 to 21 in Liaocheng, Shandong Province. The conference offered insights into the … Continued
By asianet
The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial evaluating SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon. This milestone follows Investigational Device Exemption (IDE) approval in the US in May 2022, with enrollment of the first patient occurring in Germany one week after approval. “We are very excited to finally have … Continued
By asianet
Hovione and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion’s Dispersome(R) technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the … Continued
By asianet
— Albert Wu, MD, PhD, a recognized advocate of using stem cell therapy to treat eye conditions, will advise company’s development of ocular tissue rejuvenation therapeutics Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic … Continued
By asianet
– Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union – Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the … Continued
By asianet
– Companion diagnostic would be used following potential regulatory approval of entospletinib to screen for NPM1 mutation present in approximately one-third of all patients with AML – Entospletinib is currently being studied in the Phase 3 AGILITY registrational study, with data anticipated in second half of 2023 Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated … Continued
By asianet
Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrant showing statistically significant efficacy over current standard-of-care (SOC) medications for both the overall … Continued
By asianet
SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). This comes only a few months after the company received IDE approval for SELUTION SLR in the treatment of below-the-knee (BTK) indications … Continued
By asianet
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol(R) water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for CyclASol(R) (cyclosporine ophthalmic solution), a proposed novel treatment for the signs and symptoms of dry eye … Continued
By asianet
– FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activity in vitro and in vivo – Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent antiviral concentrations have been reached in the blood plasma and lung tissues without … Continued